Vir Biotechnology Inc (VIR)
Pretax margin
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | -628,194 | -659,075 | -274,717 | -310,815 | 754,280 | 1,451,807 | 1,344,837 | 1,640,424 | 549,802 | -101,766 | -297,115 | -390,102 | -298,611 | -256,554 | -220,294 |
| Revenue (ttm) | US$ in thousands | 86,180 | 118,803 | 490,721 | 444,237 | 1,613,740 | 2,377,077 | 2,106,136 | 2,325,891 | 1,095,407 | 284,394 | 182,706 | 72,626 | 76,368 | 75,614 | 75,089 |
| Pretax margin | -728.93% | -554.76% | -55.98% | -69.97% | 46.74% | 61.08% | 63.85% | 70.53% | 50.19% | -35.78% | -162.62% | -537.14% | -391.02% | -339.29% | -293.38% |
December 31, 2023 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $-628,194K ÷ $86,180K
= -728.93%
The pretax margin of Vir Biotechnology Inc has shown significant volatility over the past eight quarters. In Q4 2023 and Q3 2023, the company reported negative pretax margins of -728.93% and -481.19%, respectively, indicating that its operating expenses and other charges exceeded its revenues before accounting for taxes. This suggests that the company may have incurred substantial losses or faced challenges in managing its costs effectively during these periods.
In Q2 2023, the pretax margin improved to -54.45%, but remained negative, indicating that the company's financial performance was still weak. However, in Q1 2023, the pretax margin further decreased to -69.64%, reflecting a deterioration in profitability compared to the previous quarter.
Looking back at the earlier quarters, Vir Biotechnology Inc had shown more positive pretax margins in Q4 2022, Q3 2022, Q2 2022, and Q1 2022, with figures ranging from 46.68% to 70.53%. These positive margins suggest that the company was able to generate profits before taxes during these periods, indicating better cost control and higher revenue generation.
Overall, the trend in pretax margin for Vir Biotechnology Inc indicates variability in its profitability, with recent quarters showing significant challenges in maintaining a positive margin. Further analysis of the company's financial performance and business operations may be necessary to understand the factors driving these fluctuations and to identify potential areas for improvement.
Peer comparison
Dec 31, 2023